Sincalid

Drug Induced Liver Injury Rank (DILIrank 2.0)

Sincalide

vNo-DILI-concern

0

No match

DOI:10.1016/j.drudis.2016.02.015

◉ Summary of Use during Lactation；Sincalide is a synthetic octapeptide analogue of cholecystokinin. Because sincalide has a molecular weight of 1143 Da, the amount in milk is likely to be low and oral absorption by the infant is unlikely because it is probably partially destroyed in the infant's gastrointestinal tract and poorly absorbed orally. The serum half-life of sincalide is less than 2 minutes, indicating that withholding breastfeeding for 10 minutes after a dose should ensure that the infant is not exposed to the drug.；◉ Effects in Breastfed Infants；Relevant published information was not found as of the revision date.；◉ Effects on Lactation and Breastmilk；Relevant published information was not found as of the revision date.

V - Various；V04 - Diagnostic agents；V04C - Other diagnostic agents；V04CC - Tests for bile duct patency；V04CC03 - Sincalide

QV - Various；QV04 - Diagnostic agents；QV04C - Other diagnostic agents；QV04CC - Tests for bile duct patency；QV04CC03 - Sincalide

Following an intravenous (bolus) injection of 0.02 mcg/kg of sincalide, maximal contraction of the gallbladder occurred in 5 to 15 minutes. Sincalide reduced gallbladder radiographic size by at least 40%, generally considered satisfactory contraction.

When injected intravenously, sincalide produces a substantial reduction in gallbladder size by causing this organ to contract. The evacuation of bile that results is similar to that which occurs physiologically in response to endogenous cholecystokinin. Like cholecystokinin, sincalide stimulates pancreatic secretion; concurrent administration with secretin increases both the volume of pancreatic secretion and the output of bicarbonate and protein (enzymes) by the gland. This combined effect of secretin and sincalide permits the assessment of specific pancreatic function through measurement and analysis of the duodenal aspirate.

M03GIQ7Z6P

SINCALIDE

Chemical Structure [CS] - Cholecystokinin

Established Pharmacologic Class [EPC] - Cholecystokinin Analog

Sincalide is a Cholecystokinin Analog.

SINCALIDE

The intravenous (bolus) administration of sincalide causes a prompt contraction of the gallbladder that becomes maximal in 5 to 15 minutes, as compared with the stimulus of a fatty meal which causes a progressive contraction that becomes maximal after approximately 40 minutes.

Limited information is available on the route of elimination of sincalide

Limited information is available on the volume of distribution of sincalide.